Howard M R
United Kingdom Transplant Service, Bristol, U.K.
Transfus Sci. 1991;12(3):123-34. doi: 10.1016/0955-3886(91)90118-M.
Severe aplastic anaemia (SAA) is frequently a lethal disease. Allogeneic marrow transplantation may offer the best chance of a cure but more than 50% of eligible patients will lack a suitable family donor. The development of large volunteer registries has established unrelated donor marrow transplantation (UD-BMT) as a possible alternative in these patients. Early clinical studies indicate that UD-BMT for SAA is associated with a significantly greater risk of graft rejection and graft-versus-host disease (GVHD) than identical sibling BMT. Current strategies for improving results of UD-BMT for SAA include improved patient selection, more precise HLA matching between recipient and unrelated donor, and the use of more intensive pre-BMT immunosuppression and GVHD prophylaxis.
重型再生障碍性贫血(SAA)通常是一种致命性疾病。异基因骨髓移植可能提供治愈的最佳机会,但超过50%的符合条件的患者将缺乏合适的家族供体。大型志愿者登记库的建立已使无关供体骨髓移植(UD-BMT)成为这些患者的一种可能替代方案。早期临床研究表明,与同卵同胞骨髓移植相比,SAA患者接受UD-BMT时发生移植物排斥和移植物抗宿主病(GVHD)的风险显著更高。目前改善SAA患者UD-BMT疗效的策略包括改进患者选择、受体与无关供体之间更精确的HLA配型,以及使用更强的移植前免疫抑制和GVHD预防措施。